#Sweden #Lund #kidney transplant #Hansa Biopharma #IDEFIRIX

Promising Idefirix Results Presented at ASN Kidney Week 2026

Hansa Biopharma AB, a leading biopharmaceutical company based in Sweden, has made headlines with the recent presentation of its Post-Authorization Efficacy and Safety (PAES) study results for Idefirix (imlifidase) at the ASN Kidney Week 2026 held in Denver, Colorado. The data was unveiled during a prestigious High-Impact Clinical Trials session, emphasizing the significance of these findings in the field of nephrology and transplantation.

The PAES study brought forth encouraging statistics, particularly in the context of graft failure-free survival rates. At the conclusion of the year following transplantation, it was reported that 90% of the patients experienced graft failure-free survival. This remarkable statistic, combined with graft and patient survival rates of 92% and 98%, respectively, underlines the potential of Idefirix to dramatically improve outcomes for those undergoing kidney transplants.

Renée Aguiar-Lucander, CEO of Hansa Biopharma, stated that the presentation underscored the scientific and clinical relevance of the study, pinpointing Idefirix as a potentially transformative option for highly sensitized patients who often face considerable challenges in securing compatible donor organs. She expressed optimism regarding the heightened interest from the transplant community in the growing body of evidence surrounding Idefirix's benefits.

Understanding the Study and Its Impact

The PAES trial targeted deeply sensitized kidney transplant patients—those with pre-existing antibodies that complicate their chances of finding a suitable donor. This trial was crucial as these patients typically find themselves at a higher risk of graft loss due to their immunological profile. The study reported that Idefirix effectively converted a positive crossmatch to a negative, thereby facilitating transplantation for those who would otherwise remain on waiting lists indefinitely.

Conducted on a cohort of 50 patients, the primary objective was to analyze graft failure-free survival one year post-transplant. Secondary outcomes included evaluations of kidney function, patient survival, delayed graft function (DGF), and antibody-mediated rejection (AMR). Intriguingly, while DGF affected 40% of the study population, the median duration reported was relatively short at just 14 days, and AMR was registered in 56% of recipients without any associated allograft losses.

A Closer Look at Results

The efficacy of Idefirix not only prevails from the survival rates but also from its safety profile, which matched the observations from earlier trials with no new safety signals raised. As reported, none of the Idefirix infusions were halted due to infusion reactions, further establishing the drug's tolerability.

Dr. Oriol Bestard MD PhD from Vall d'Hebron University Hospital, who was closely involved in the PAES study, highlighted the significance of these findings in combating the unique challenges faced by highly sensitized patients. These results provide substantial evidence that Idefirix can enable transplantation and improve access for patients who have long faced barriers to receiving a donor organ.

The Broader Context of Kidney Transplantation

Kidney transplantation is often regarded as the gold standard for treating end-stage renal disease (ESRD), a condition affecting millions globally. In the U.S. and Europe, there are approximately 170,000 individuals on transplant waiting lists, and among these, 10-15% are classified as highly sensitized patients. These patients contend with a markedly reduced likelihood of finding a match, resulting in extended waiting periods with potentially dire consequences.

Idefirix, derived from the enzyme imlifidase, has been marketed in Europe since its conditional approval in 2020. It promptly inactivates IgG antibodies, opening a crucial temporal window enabling transplantation for patients typically labeled as difficult to transplant due to HLA incompatibilities. As noted by the researchers, Idefirix represents a beacon of hope for this challenging patient group, marking a paradigm shift in how certain immunological profiles are addressed in transplantation.

Hansa Biopharma continues to pioneer advancements in immunomodulatory therapies geared toward improving transplantation outcomes, not just for kidney transplants but across broader immunological disorders. With the data presented at ASN Kidney Week 2026, the company aims to underscore its commitment to fostering innovative solutions that address significant unmet medical needs in transplantation and beyond.

Conclusion

As the transplant community digests these significant findings, the anticipation surrounding Idefirix escalates. With ongoing studies and discussions at major medical congresses such as the ASN Kidney Week, Hansa Biopharma is poised to solidify its standing as a transformative force in kidney transplantation, fostering a brighter future for highly sensitized patients.

For more detailed information about the PAES study, interested parties can refer to ClinicalTrials.gov (NCT05369975).